or Try an Advanced Search...

    Technical Analysis for RNAC - Cartesian Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 21.03 0.62% 0.13
    RNAC closed up 0.62 percent on Friday, April 26, 2024, on 1.97 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: May 2
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical RNAC trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Doji - Bearish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Up 5 Days in a Row Strength 0.00%
    Outside Day Range Expansion 0.62%
    Wide Bands Range Expansion 0.62%
    Overbought Stochastic Strength 0.62%
    Older End-of-Day Signals for RNAC ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 15 hours ago
    Rose Above Previous Day's High about 16 hours ago
    Up 3% about 16 hours ago
    Up 2% about 16 hours ago
    60 Minute Opening Range Breakout about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RNAC Chart by TradingView
    Basic chart:

    Profile

    Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases

    Is RNAC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
    Apr 10 Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
    Apr 4 Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    Mar 28 Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
    Mar 21 Cartesian Therapeutics Director Acquires 3.2% More Stock
    Mar 19 LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
    Mar 7 Cartesian Therapeutics GAAP EPS of -$1.66 misses by $1.64, revenue of $26M beats by $15.4M
    Mar 7 Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    Mar 6 Cartesian Therapeutics to Participate in Upcoming Investor Conferences
    Mar 5 Cartesian Therapeutics Announces New Employment Inducement Grant
    See more RNAC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 42.6
    52 Week Low 11.665
    Average Volume 62,760
    200-Day Moving Average 26.98
    50-Day Moving Average 19.27
    20-Day Moving Average 17.48
    10-Day Moving Average 19.30
    Average True Range 2.02
    RSI (14) 73.75
    ADX 29.89
    +DI 36.07
    -DI 15.94
    Chandelier Exit (Long, 3 ATRs) 15.67
    Chandelier Exit (Short, 3 ATRs) 17.74
    Upper Bollinger Bands 22.39
    Lower Bollinger Band 12.58
    Percent B (%b) 0.86
    BandWidth 56.13
    MACD Line 0.48
    MACD Signal Line -0.10
    MACD Histogram 0.5773
    Fundamentals Value
    Market Cap 3.41 Billion
    Num Shares 162 Million
    EPS -0.29
    Price-to-Earnings (P/E) Ratio -72.52
    Price-to-Sales 3.26
    Price-to-Book 1.83
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.58
    Resistance 3 (R3) 22.64 22.19 22.32
    Resistance 2 (R2) 22.19 21.80 22.16 22.23
    Resistance 1 (R1) 21.61 21.55 21.90 21.55 22.15
    Pivot Point 21.16 21.16 21.31 21.13 21.16
    Support 1 (S1) 20.58 20.77 20.87 20.52 19.91
    Support 2 (S2) 20.13 20.52 20.10 19.83
    Support 3 (S3) 19.55 20.13 19.74
    Support 4 (S4) 19.49